CE Mark for Image Guided Programming Software for Deep Brain Stimulation

Boston’s Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions Boston Scientific Corporation has obtained a CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology, which when used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) Systems, can provide…

King’s Parkinson’s Charitable Fund launches

Twenty years ago, Professor K Ray Chaudhuri and colleagues wrote in ACNR about the often neglected non-motor symptoms of Parkinson’s which impact so much on a patient’s quality of life – symptoms such as pain, poor sleep, depression, anxiety, sexual dysfunction and autonomic problems. Two decades on, the newly launched King’s Parkinson’s Charitable Fund aims…

How can scientists model the human brain?

bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…

WFNR Franz Gerstenbrand Award 2024 Winner

Dr Christian Endisch, a physician with a neurology residency at the department of Neurology and Experimental Neurology Charité Universitätsmedizin in Berlin, Germany, is the winner of the 2024 World Federation of Neurorehabilitation (WFNR) Franz Gerstenbrand Award. Announced this month at the 13th World Congress for Neurorehabilitation in Vancouver, Canada, Dr Endisch said: “I’m delighted to…

Urgent findings from head-CT scans prioritised by AI at NHS Greater Glasgow and Clyde

First of four NHS sites roll out head-CT AI to highlight critical head injury scans A new multi-NHS site initiative went live in April, aiming to improve radiology report turnaround times for non-contrast CT head scans by creating prioritised reporting worklists of critical findings. This will allow Emergency Department (ED) clinicians at the Queen Elizabeth…

Trofinetide for Rett Syndrome – new drug submission in Canada 

23 April 2024: Acadia Pharmaceuticals Inc has announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and…

Clinical trial for ALS patients

10 April 2024: Axoltis Pharma, a French biopharmaceutical company dedicated to developing therapeutic solutions for neurodegenerative diseases, today announced the authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study. This phase II clinical trial of drug candidate NX210c in patients with Amyotrophic Lateral Sclerosis (ALS) is the…

Position of stroke patient’s head before surgery may improve neurological function

Research Highlights: from American Stroke Association International Stroke Conference, February 2024 Positioning patients with large vessel ischaemic (clot-caused) stroke with their heads flat (0-degrees) before surgery to remove the blood clot resulted in significant improvements in neurological function, compared to patients whose heads were elevated (at a 30-degree angle), according to science presented on February…